Role of aging in Blood-Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19.
Role of aging in Blood-Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19.
复制标题
DOI:
10.1186/s12987-022-00357-5
复制
发表时间:
2022-08-18
影响因子:
7.3
通讯作者:
Stipursky, Joice
中科院分区:
文献类型:
--
作者:
Adesse, Daniel;Gladulich, Luis;Alvarez-Rosa, Liandra;Siqueira, Michele;Marcos, Anne Caroline;Heider, Marialice;Motta, Caroline Soares;Torices, Silvia;Toborek, Michal;Stipursky, Joice
COVID-19, which is caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), has resulted in devastating morbidity and mortality worldwide due to lethal pneumonia and respiratory distress. In addition, the central nervous system (CNS) is well documented to be a target of SARS-CoV-2, and studies detected SARS-CoV-2 in the brain and the cerebrospinal fluid of COVID-19 patients. The blood–brain barrier (BBB) was suggested to be the major route of SARS-CoV-2 infection of the brain. Functionally, the BBB is created by an interactome between endothelial cells, pericytes, astrocytes, microglia, and neurons, which form the neurovascular units (NVU). However, at present, the interactions of SARS-CoV-2 with the NVU and the outcomes of this process are largely unknown. Moreover, age was described as one of the most prominent risk factors for hospitalization and deaths, along with other comorbidities such as diabetes and co-infections. This review will discuss the impact of SARS-CoV-2 on the NVU, the expression profile of SARS-CoV-2 receptors in the different cell types of the CNS and the possible role of aging in the neurological outcomes of COVID-19. A special emphasis will be placed on mitochondrial functions because dysfunctional mitochondria are also a strong inducer of inflammatory reactions and the “cytokine storm” associated with SARS-CoV-2 infection. Finally, we will discuss possible drug therapies to treat neural endothelial function in aged patients, and, thus, alleviate the neurological symptoms associated with COVID-19.
登录
查看更多内容
影响因子:
--
作者:
Andersson MI;Arancibia-Carcamo CV;Auckland K;Baillie JK;Barnes E;Beneke T;Bibi S;Brooks T;Carroll M;Crook D;Dingle K;Dold C;Downs LO;Dunn L;Eyre DW;Gilbert Jaramillo J;Harvala H;Hoosdally S;Ijaz S;James T;James W;Jeffery K;Justice A;Klenerman P;Knight JC;Knight M;Liu X;Lumley SF;Matthews PC;McNaughton AL;Mentzer AJ;Mongkolsapaya J;Oakley S;Oliveira MS;Peto T;Ploeg RJ;Ratcliff J;Robbins MJ;Roberts DJ;Rudkin J;Russell RA;Screaton G;Semple MG;Skelly D;Simmonds P;Stoesser N;Turtle L;Wareing S;Zambon M
通讯作者:
Zambon M
影响因子:
4.6
作者:
Bertrand L;Dygert L;Toborek M
通讯作者:
Toborek M
影响因子:
4.8
作者:
Buxbaum, JD;Liu, KN;Black, RA
通讯作者:
Black, RA
影响因子:
21.3
作者:
Bleazard, W;McCaffery, JM;Shaw, JM
通讯作者:
Shaw, JM
影响因子:
0.6
作者:
Abdelrahman, Heba S.;Safwat, Ahmed M.;Alsagheir, Mahmoud M.
通讯作者:
Alsagheir, Mahmoud M.